NCT05167552 is a Phase 1, PHASE2 clinical trial of Olfactory mucosa-derived mesenchymal stem cells in Allergic Rhinitis, sponsored by Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus.

What drugs are being tested in NCT05167552?

Interventions in NCT05167552: Olfactory mucosa-derived mesenchymal stem cells, Standard treatment of type Allergic Rhinitis according to the clinical protocols, Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols.

What condition does NCT05167552 study?

NCT05167552 studies Allergic Rhinitis, Rhinosinusitis Chronic.

Is NCT05167552 still recruiting?

NCT05167552 is currently status unknown. Last updated 19 January 2022.

Last reviewed 2022-01-19 · How we verify

NCT05167552

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Allergic Rhinitis and Chronic Polypous Rhinosinusitis With Olfactory Mucosa-derived Mesenchymal Stem Cells

Status unknown Phase 1, PHASE2 Last updated 19 January 2022

What this trial tests

Phase 1, PHASE2 trial testing Olfactory mucosa-derived mesenchymal stem cells in Allergic Rhinitis in 60 participants. Status unknown.

Timeline

1 March 2022

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 March 2022
Primary completion	31 December 2023
Estimated completion	31 December 2023

Drugs / interventions tested

Olfactory mucosa-derived mesenchymal stem cells — full drug profile →
Standard treatment of type Allergic Rhinitis according to the clinical protocols
Standard treatment of type Chronic Polypous Rhinosinusitis according to the clinical protocols

Conditions studied

Allergic Rhinitis — all drugs for Allergic Rhinitis →
Rhinosinusitis Chronic — all drugs for Rhinosinusitis Chronic →

Sponsor

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

Who can join

Adults 18 to 80, any sex, with Allergic Rhinitis or Rhinosinusitis Chronic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Treatment of patients with allergic rhinitis and chronic polypous rhinosinusitis with olfactory mucosa-derived mesenchymal stem cells

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Stem cell therapies in the clinic.
Acharya S, Shaha S, Bibbey MG, Mukherji M, et al · · 2025 · cited 3× · PMID 40385529 · DOI 10.1002/btm2.70000
[Research advances of mesenchymal stem cell in allergic rhinitis].
Li W, Wang Y, Cheng F, Qi X, et al · · 2024 · cited 1× · PMID 38686485 · DOI 10.13201/j.issn.2096-7993.2024.05.018

Verify or expand the search:

Other trials of Olfactory mucosa-derived mesenchymal stem cells

Trials testing the same drug.

NCT05535803 — Treatment of Laryngotracheal Stenosis Using Mesenchymal Stem Cells · Phase 2 · unknown
NCT03130374 — Treatment of Laryngotracheal Stenosis Using Mesenchymal Stem Cells · Phase 1, PHASE2 · completed

Other recruiting trials for Allergic Rhinitis

Currently open trials in the same condition.

NCT07453615 — Effect of AI(Artificial Intelligence)-Based Storytelling Video on Anxiety and Fear During Skin Prick Test in Children · NA · recruiting
NCT07419230 — Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project · NA · recruiting
NCT06960382 — Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Ast · Phase 1, PHASE2 · recruiting
NCT07455968 — Free Diving Breathing Training in Allergic Rhinitis · NA · active not recruiting
NCT07115342 — Effect of Combined Probiotics and Vitamin D on Symptoms of Allergic Rhinitis · NA · recruiting

Other Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus trials

Trials by the same sponsor.

NCT06167564 — Allergy Diagnostic Test Based on Microchip Technology · NA · unknown
NCT05654766 — Assesment of the Functional Activity of Platelets for the Differential Diagnosis of Thrombocytopathies · unknown
NCT05520125 — Treatment of Patients With Bone Tissue Defects Using Mesenchymal Stem Cells Enriched by Extracellular Vesicles · Phase 1, PHASE2 · unknown
NCT05520112 — Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells · Phase 1, PHASE2 · unknown
NCT05214014 — Treatment of Systemic Sclerosis With Autologous Regulatory Т-cells · Phase 1, PHASE2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05167552 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Last refreshed: 19 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05167552.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing